AUTHORS
Jack Alexander Stover, MD, Guilin Tang, MD, PhD,FACMG2, Hannah Goulart, MD3, Naval Daver, MD4, Nitin Jain, MD5, Sherry Pierce, BSN, RN6, Sanam Loghavi, MD7, Guillermo Montalban-Bravo, MD8, Branko Cuglievan, MD9, Muzaffar Qazilbash, MD10, Tapan Kadia I, MD11, Guillermo Garcia-Manero, MD12, Courtney DiNardo, MD, MSCE13, Naveen Pemmaraju, MD14
AFFILIATIONS
1 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
2 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
3 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
4 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
5 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
6 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
7 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
8 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
9 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
10 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
11 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
12 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
13 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
14 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
ABSTRACT
Background: Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare, clinically aggressive hematologic malignancy derived from immature plasmacytoid dendritic cells with historically poor prognosis. The advent of modern therapies targeting CD123 has led to improved patient outcomes, but relapses remain common and there are no approved therapies beyond CD123-monotherapy targeted agents (Pemmaraju JCO, 2026). Therefore, there is an urgent, unmet need to identify novel therapeutic targets beyond CD123. One putative candidate is MYB, a hematopoietic transcription factor responsible for cell cycle regulation, which has been reported to be rearranged in many pediatric/adolescent young adult (AYA) BPDCN pts, but thus far, little is known about its frequency in adult BPDCN pts (Suzuki Leukemia, 2017; Khanlari M Haematologica, 2026; Booth JCI Insight, 2024). Importantly, MYB rearrangements are frequently missed by conventional karyotyping and routine next-generation sequencing (NGS). In this study, we utilized optical genome mapping (OGM) to evaluate the comprehensive cytogenomic profile of BPDCN with the aim of identifying potential novel, therapeutically actionable, genetic alterations.
Methods: OGM (Bionano Genomics, CA, USA) was performed on bone marrow samples with ≥20% involvement by BPDCN from January 2023 to July 2026. Demographic, clinical, conventional cytogenetic, NGS, and survival data were obtained. Complete remission (CR) duration was calculated from the first documented CR to loss of CR or death. Given the sample size, comparisons between MYB and non-MYB BPDCN pts were descriptive.
Results: We assessed OGM on 6 consecutive BPDCN pts with (5 males;1 female), with a median age of 67 years [range, 20-86]. At diagnosis, involvement of skin, bone marrow, and/or lymph nodes was seen in 4/6 (67%), peripheral blood in 3/6 (50%), and CNS in 1/6 (17%) of pts. Tumor immunophenotyping demonstrated CD4+, CD56+, and CD123+ in 6/6 (100%), CD38+ and TCL-1+ in 5/6 (83%), and CD303+ in 4/6 (67%) of pts. All cases harbored 3 or more cytogenomic abnormalities detected by OGM. Common recurrent abnormalities included del(12p)/ETV6 loss (83%), monosomy 9 (67%), del(5q) (67%), monosomy 13 (50%), t(6;v)(q23.3;v)/MYB rearrangement (50%), and chromoanagenesis (33%). The putative partner genes involved in MYB rearrangements were 11q2.2/DCPS, 1q21.2/PLEKHO1, and 1q31.3/UGCG, each identified in one case. Importantly, MYB aberrations were detected by conventional karyotype in only 1/3 of pts. Complex karyotypes were present in 1/3 of MYB and 2/3 of non-MYB pts. Among MYB pts: one had concurrent DDX41, NRAS, TET2, and ZRSR2 mutations identified on NGS panel; the second pt had ASXL1, TET2, and ZRSR2 mutations; the third pt had an NRAS mutation. Among non-MYB pts, one had concurrent ASXL1, DNMT3A, CUX1, SH2B3, SF3B1, and TET2 mutations. Another had IKZF1, NRAS, and TET2 mutations. The last had SRSF2, TET2, and TP53 mutations.
Frontline regimens for MYB pts were HyperCVAD, tagraxofusp+HyperCVAD+venetoclax, and azacitidine+venetoclax. Regimens for non-MYB pts were tagraxofusp, tagraxofusp+venetoclax, and azacitidine+venetoclax. The overall response rate (CR plus CR with incomplete count recovery) to induction therapy was 83% (100% in MYB pts and 67% in non-MYB pts). All pts eventually achieved CR. Median CR duration was 6.7 months [range, 3.5-10.7] versus 4.0 months [range, 3.6-13.9] in MYB and non-MYB pts, respectively. One non-MYB pt proceeded to allogeneic hematopoietic stem cell transplant (HSCT) after CR and remained in remission until death. No other pts received HSCT. All other pts ultimately relapsed. In the salvage setting, notably, none of the pts had a major response to therapy. Median OS from diagnosis was 13.5 months [range, 10.9-17.5] in MYB pts versus 15.2 months [range, 6.1-17.9] in non-MYB pts. All pts were deceased at last follow-up.
Conclusions: OGM comprehensively characterized the cytogenomic landscape of BPDCN, including frequent complex genomic alterations, recurrent copy-number changes and frequent MYB rearrangements. Our findings indicate that there is an unexpectedly high and unappreciated incidence of MYB rearrangements in this older BPDCN adult population. The recent development of first-generation MYB-targeted agents represents a potential investigational opportunity to translate this novel finding into new treatment approaches for pts in this rare, poor-prognosis subset without available standard therapies.
DISCLOSURES
Jack Alexander Stover, MD: No relevant conflicts of interest to declare.